Sodium-Glucose Cotransporter-2 Inhibitors—Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials

Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease (CKD) and end-stage kidney disease worldwide. In Japan, the proportion of new patients requiring dialysis due to DKD has remained unchanged over the past five years. Early diagnosis and treatment are extremely important for...

Descripción completa

Detalles Bibliográficos
Autores principales: Gohda, Tomohito, Murakoshi, Maki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696577/
https://www.ncbi.nlm.nih.gov/pubmed/36430228
http://dx.doi.org/10.3390/ijms232213749

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696577/
https://www.ncbi.nlm.nih.gov/pubmed/36430228
http://dx.doi.org/10.3390/ijms232213749

Ejemplares similares